secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001564590-22-017653
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q1 rev $837M (+8%); cuts FY22 EPS guidance to $8.11-$8.35 on vet capacity, forex, R&D charge
--------------------------------------------------------------------------------

- Q1 EPS $2.27 (-3% reported, +3% comparable); revenue $837M (+8% reported and organic).
- CAG Diagnostics recurring revenue +9% organic; record Q1 premium instrument placements; capital instrument rev +22% organic.
- FY22 revenue outlook cut to $3,390-$3,465 (5.5%-8% reported growth); organic growth 7.5%-10%.
- FY22 EPS outlook $8.11-$8.35 includes $0.72 discrete R&D charge, $0.10 forex, $0.05 interest; prior guidance implied down.
- U.S. same-store clinical visits declined 2% in Q1 vs +13% prior year; practice revenue +6% vs +16%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000156459022017653/0001564590-22-017653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000156459022017653/idxx-8k_20220504.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-017653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer